872728-81-9 Dabigatran etexilate mesylate 98%

BDR Group of companies has grown steadily and become a house-hold name in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. We are recognized as a “niche” player in manufacturing of Pharmaceutical APIs and for our renowned new age formulations. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.

BDR Group focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, which are its dream segments.

Over the years, BDR has built an undeniable reputation for its specialization in early identification, development and introduction of new molecules, in a continuous endeavor to make globally available high cost medicines to local masses at affordable prices;

Innovation and development are the inalienable cornerstones of BDR group. We invest heavily in R&D activities, possess state–of-the-art API and Formulation development centers accredited by the DSIR, Government of India. Our facilities are in a state of constant & continuous upgradation, so as to keep up and meet with the constantly growing demands of the dynamic International scenario. Blending of human skill and innovative expertise of BDR often acts as a catalyst for development of desired modern technology and setting up of world class facilities.